View on Pubmed.gov 34149679 | View on doi.org 10.3389/fimmu.2...
Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
- Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- Medical Examination Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Department of Medical Administration, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- Department of Medical Administration, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- CAN Community Health, Sarasota, FL, United States.
- The University of Central Florida College of Medicine, Orlando, FL, United States.
Abstract
Dysregulation of immune response was observed in COVID-19 patients. Thymosin alpha 1 (Tα1) is used in the management of COVID-19, because it is known to restore the homeostasis of the immune system during infections and cancers. We aim to observe the longitudinal changes in T lymphocyte subsets and to evaluate the efficacy of Tα1 for COVID-19. A retrospective study was conducted in 275 COVID-19 patients admitted to Shanghai public health clinical center. The clinical and laboratory characteristics between patients with different T lymphocyte phenotypes and those who were and were not treated with Tα1 were compared. Among the 275 patients, 137 (49.8%) were males, and the median age was 51 years [interquartile range (IQR): 37-64]. A total of 126 patients received Tα1 therapy and 149 patients did not. There were 158 (57.5%) patients with normal baseline CD4 counts (median:631/μL, IQR: 501~762) and 117 patients (42.5%) with decreased baseline CD4 counts (median:271/μL, IQR: 201~335). In those with decreased baseline CD4 counts, more patients were older (p<0.001), presented as critically ill (p=0.032) and had hypertension (p=0.008) compared with those with normal CD4 counts. There was no statistical difference in the duration of virus shedding in the upper respiratory tract between the two groups (p=0.214). In both the normal (14 11, p=0.028) and the decreased baseline CD4 counts group (15 11, p=0.008), duration of virus clearance in the patients with Tα1 therapy was significantly longer than that in those without Tα1 therapy. There was no significant difference in the increase of CD4+ (286 326, p=0.851) and CD8+ T cell (154 170, p=0.842) counts in the recovery period between the two groups with or without Tα1 therapy. Multivariate linear regression analysis showed that severity of illness (p<0.001) and Tα1 therapy (p=0.001) were associated with virus clearance. In conclusion, reduction of CD4+ T and CD8+ T cell counts were observed in COVID-19 patients. Tα1 may have no benefit on restoring CD4+ and CD8+ T cell counts or on the virus clearance. The use of Tα1 for COVID-19 need to be more fully investigated.
References
J Infect Dis. 2020 May 11;221(11):1762-1769
Biomed Res Int. 2016;2016:9508493
Lancet. 2020 Aug 15;396(10249):479-488
EBioMedicine. 2020 Jul;57:102885
Cited by 23 citations (total)
Review Journal Article
COVID-19 and beyond: Reassessing the role of thymosin alpha1 in lung infections.
Electronic publication date April 4, 2023
Marina M Bellet [...] Claudio Costantini et al.
The recent COVID-19 pandemic has catalyzed the attention of the scientific community to the long-standing issue of lower respiratory tract...
Journal Article Review
Sepsis: the evolution of molecular pathogenesis concepts and clinical management.
Electronic publication date February 24, 2025
Zhongxue Feng [...] Wei Zhang et al.
The mortality rate of sepsis is approximately 22.5%, accounting for 19.7% of the total global mortality. Since Lewis Thomas proposed...
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
Copyright
Copyright © 2021 Wang, Chen, Zhu, Liu, Qi, Shen, Zhang, Xu, Li, Qian, Steinhart and Lu.